Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

BACKGROUND: We studied the concomitant use of single antiplatelet therapy (SAPT) on the efficacy and safety of the anti‐Xa agent edoxaban in patients with atrial fibrillation (AF). METHODS AND RESULTS: ENGAGE AF‐TIMI 48 was a randomized trial that compared 2 dose regimens of edoxaban with warfarin....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Am Heart Assoc
Glavni autori: Xu, Haiyan, Ruff, Christian T., Giugliano, Robert P., Murphy, Sabina A., Nordio, Francesco, Patel, Indravadan, Shi, Minggao, Mercuri, Michele, Antman, Elliott M., Braunwald, Eugene
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2016
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802446/
https://ncbi.nlm.nih.gov/pubmed/26908401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.115.002587
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items